• Explore /
  • Poster
  • / Phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients progressing after docetaxel treatment: Preliminary toxicity analysis (SOGUG-CABASEM trial).

Phase II study of weekly cabazitaxel for "unfit" metastatic castration resistant prostate cancer patients progressing after docetaxel treatment: Preliminary toxicity analysis (SOGUG-CABASEM trial).

Abstract Poster

Authors

null

Miguel Angel Climent Duran

Fundacion Instituto Valenciano de Oncología, Valencia, Spain

Miguel Angel Climent Duran , Begoña Perez-Valderrama , Eva Fernandez Parra , Begoña Mellado , Montserrat Domenech , Ovidio Fernandez Calvo , Urbano Anido , Susana Hernando Polo , Jose Angel Arranz , Cristina Caballero , Maria Ochoa de Olza , Daniel E. Castellano

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session A: Prostate Cancer

Track

Prostate Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT01518283

Citation

J Clin Oncol 32, 2014 (suppl 4; abstr 190)

DOI

10.1200/jco.2014.32.4_suppl.190

Abstract #

190

Poster Bd #

L11

Abstract Disclosures

Similar Posters

First Author: Ovidio Fernandez Calvo

First Author: Padmanee Sharma

First Author: Kim van der Zande

First Author: Miguel Angel Climent Duran